180 related articles for article (PubMed ID: 27539794)
1. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.
Iberri DJ; Kwong BY; Stevens LA; Coutre SE; Kim J; Sabile JM; Advani RH
Br J Haematol; 2018 Jan; 180(1):164-166. PubMed ID: 27539794
[No Abstract] [Full Text] [Related]
2. More About the Risk of Ibrutinib-associated Bleeding.
Paolini A; Coluccio V; Luppi M; Marietta M
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):326-327. PubMed ID: 28161591
[No Abstract] [Full Text] [Related]
3. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
[No Abstract] [Full Text] [Related]
4. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
5. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
6. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
7. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
8. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
9. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Thorp BC; Badoux X
Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
[TBL] [Abstract][Full Text] [Related]
10. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
11. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
12. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
13. How I treat CLL patients with ibrutinib.
Brown JR
Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
15. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
16. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
17. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
18. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.
Jani P; Vissing MB; Ahmed S; Sluzevich JC; Aulakh S; Alegria V; Ailawadhi M; Chanan-Khan A; Ailawadhi S
J Oncol Pract; 2018 Jun; 14(6):387-388. PubMed ID: 29558252
[No Abstract] [Full Text] [Related]
19. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
